The development of glioma vaccines aims to target tumor-specific antigens similar to those recognized by Chimeric Antigen Receptor T (CAR-T) cells, such as EGFR variant III (EGFRvIII) and Interleukin-13 Receptor Alpha 2 (IL-13Rα2). Here, IL13RA2 is linked to central nervous system cancer.